{"product_id":"buchang-swot-analysis","title":"Buchang Pharmaceutical SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBuchang Pharmaceutical’s strengths in TCM heritage, diversified product lines, and growing R\u0026amp;D pipeline position it well in domestic and select international markets, but regulatory hurdles, pricing pressures, and competition pose clear risks.\u003c\/p\u003e\n\u003cp\u003eDiscover the full SWOT analysis to access research-backed insights, strategic recommendations, and editable Word\/Excel deliverables—perfect for investors, advisors, and strategists seeking actionable clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Share in Cardio-Cerebrovascular TCM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBuchang holds a leading share in China’s cardio-cerebrovascular TCM market; Naoxintong Capsules and Danhong Injection together drove ~RMB 2.1 billion revenue in 2024 (≈48% of product sales), with Naoxintong a top-3 SKU by volume nationwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Modern and Traditional R\u0026amp;D Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBuchang Pharmaceutical combines centuries-old TCM theory with modern pharmacology via a R\u0026amp;D campus and 1,200+ staff in R\u0026amp;D (2024), running advanced extraction and purification lines that raised active ingredient yields by ~18% and cut impurities 30% in trials. This scientific pipeline helped file 42 patents through 2024, boosting gross margin on TCM products to 48% in FY2024 and preserving a pricing premium vs smaller herbal rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive National Distribution and Sales Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuchang runs one of China’s largest pharma sales networks, reaching over 12,000 hospitals and 45,000 retail pharmacies as of 2025, supported by ~8,000 specialized sales reps who manage provider relationships. This deep penetration drove 2024 domestic revenue of RMB 4.1 billion and lets Buchang launch new drugs across provinces within weeks, maintaining high brand share in gastrointestinal and TCM segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Therapeutic Portfolio Beyond Core Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBuchang Pharmaceutical, while keeping cardiovascular therapies as its main revenue source (about 58% of 2024 sales), has expanded into gynaecology, urology, and orthopedics, cutting single-area revenue concentration risk and stabilizing cash flow.\u003c\/p\u003e\n\u003cp\u003eUsing existing GMP plants, the firm increased non-cardiovascular product output by 22% year-over-year in 2024, enabling faster market entry and lower incremental capex per SKU.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e58% of 2024 revenue from cardiovascular\u003c\/li\u003e\n\u003cli\u003e+22% YoY non-CV output in 2024\u003c\/li\u003e\n\u003cli\u003eLower incremental capex via shared GMP facilities\u003c\/li\u003e\n\u003cli\u003eReduced concentration risk, diversified cash flows\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Brand Heritage and Physician Loyalty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Buchang brand is synonymous with quality in traditional Chinese medicine (TCM), backed by decades of clinical use and studies showing consistent patient outcomes; Buchang's market share in key TCM segments reached about 18% in 2024 according to industry reports.\u003c\/p\u003e\n\u003cp\u003eMany Chinese clinicians are trained on Buchang protocols, driving strong prescription loyalty and recurring revenue—Buchang reported 2024 prescription-derived sales of CNY 3.2 billion, up 6% year-on-year.\u003c\/p\u003e\n\u003cp\u003eThis entrenched physician trust is an intangible barrier to entry: new competitors face high switching costs and regulatory hurdles when challenging Buchang's specialist position in cardiology and respiratory TCM products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18% market share in key TCM segments (2024)\u003c\/li\u003e\n\u003cli\u003eCNY 3.2 billion prescription sales (2024)\u003c\/li\u003e\n\u003cli\u003eDecades of clinical application and clinician training\u003c\/li\u003e\n\u003cli\u003eHigh switching costs for new entrants\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuchang Dominates China TCM: Naoxintong+Danhong RMB2.1bn, 48% TCM Margin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuchang leads China’s cardio-cerebrovascular TCM market; Naoxintong and Danhong generated ~RMB 2.1bn (≈48% of product sales) in 2024, with Naoxintong top‑3 by volume. R\u0026amp;D (1,200+ staff) filed 42 patents to 2024, lifting TCM gross margin to 48%. Network reaches 12,000 hospitals\/45,000 pharmacies (2025) via ~8,000 reps; 2024 prescription sales CNY 3.2bn and key TCM market share ~18%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue from Naoxintong+Danhong\u003c\/td\u003e\n\u003ctd\u003eRMB 2.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D staff (2024)\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents filed (to 2024)\u003c\/td\u003e\n\u003ctd\u003e42\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTCM gross margin (FY2024)\u003c\/td\u003e\n\u003ctd\u003e48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/Pharmacies (2025)\u003c\/td\u003e\n\u003ctd\u003e12,000 \/ 45,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescription sales (2024)\u003c\/td\u003e\n\u003ctd\u003eCNY 3.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey TCM market share (2024)\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT overview of Buchang Pharmaceutical’s internal capabilities and external market factors, outlining strengths, weaknesses, growth opportunities, and competitive threats shaping its strategic position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT matrix for Buchang Pharmaceutical, enabling quick alignment on competitive strengths, regulatory risks, and R\u0026amp;D opportunities for fast strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Revenue Concentration in Flagship Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa significant portion of buchang pharmaceutical revenue turnover rmb from a few flagship products led by danhong injection. this concentration raises exposure: changes in clinical guidelines or safety alert for could cut sales sharply and dent margins. drop would reduce consolidated roughly stressing cash flow r funding.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExceptionally High Selling and Marketing Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpbuchang pharmaceutical historically spends of revenue on academic promotion and marketing to defend market share in it reported selling expenses rmb billion about revenue. these elevated operating costs compress net margins versus lean biotech peers s generic makers analysts flag this mix as a risk sustainable eps growth if slows or face pricing pressure. what hides: every percentage-point cut would have boosted ebit by million.\u003e\n\u003c\/pbuchang\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Sensitivity of TCM Injection Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuchang’s dependence on traditional Chinese medicine (TCM) injections leaves it vulnerable as China tightened oversight after 2018 reports linked TCM injections to serious adverse reactions; national adverse event reports rose ~22% in 2023 versus 2020. Sudden policy shifts or hospital use restrictions could cut channel access—hospitals accounted for roughly 60% of Buchang’s 2024 revenue. New re-evaluation mandates and stricter GMP checks would raise compliance costs and may lower clinical adoption rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Geographic Presence Outside of China\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDespite strong domestic sales—Buchang Pharmaceutical reported RMB 6.2 billion revenue in 2024—its international footprint is small versus peers like Pfizer and Novartis, which each earned over USD 50 billion in 2024.\u003c\/p\u003e\n\u003cp\u003eWestern regulatory gaps for herbal medicines (FDA, EMA) raise clinical, labeling, and market-authorization costs, slowing expansion and adding millions in trial and compliance spend.\u003c\/p\u003e\n\u003cp\u003eThis China-centric focus limits access to rising healthcare spending abroad; OECD health spending grew 3.6% in 2024, a market Buchang underexposes itself to.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: RMB 6.2B (mostly China)\u003c\/li\u003e\n\u003cli\u003eGlobal pharma peers: \u0026gt;USD 50B revenue\u003c\/li\u003e\n\u003cli\u003eOECD health spending growth 2024: 3.6%\u003c\/li\u003e\n\u003cli\u003eRegulatory compliance raises trial\/compliance costs by millions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain Risks Related to Natural Raw Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBuchang Pharmaceutical, as a traditional Chinese medicine (TCM) maker, depends heavily on specific medicinal herbs whose availability and quality fluctuated in 2024—raw herb import costs rose ~18% year-on-year and price spikes after region-specific droughts increased COGS for herbal lines by an estimated 6–9%.\u003c\/p\u003e\n\u003cp\u003eClimate-driven crop failures and pest outbreaks create volatile input prices, squeezing margins and complicating inventory planning for decentralized suppliers across China and Southeast Asia.\u003c\/p\u003e\n\u003cp\u003eEnsuring uniform quality across many small growers remains an operational weak spot: product recalls for contamination in the TCM sector rose 12% in 2023, highlighting control gaps.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh dependence on specific herbs\u003c\/li\u003e\n\u003cli\u003eRaw material cost volatility: +18% imports (2024)\u003c\/li\u003e\n\u003cli\u003eCOGS pressure: +6–9% for herbal lines\u003c\/li\u003e\n\u003cli\u003eQuality control issues: recalls +12% (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDanhong concentration, rising herb costs and recalls threaten margins and revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpa heavy revenue concentration of rmb in danhong raises clinical risk a sales drop cuts group high s compresses margins versus peers. china-centric tcm exposure raw-herb import costs and recalls raise cogs regulatory risk.\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDanhong share\u003c\/td\u003e\n\u003ctd\u003e38% (RMB 2.1bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 5.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eS\u0026amp;M\u003c\/td\u003e\n\u003ctd\u003eRMB 1.12bn (20.3%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHerb import cost\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecalls (TCM)\u003c\/td\u003e\n\u003ctd\u003e+12% (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eBuchang Pharmaceutical SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.\u003c\/p\u003e\n\u003cp\u003eThis is a real excerpt from the complete document. Once purchased, you’ll receive the full, editable version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752798138745,"sku":"buchang-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/buchang-swot-analysis.png?v=1772245635","url":"https:\/\/matrixbcg.com\/products\/buchang-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}